GleamWall
中文EN

ELAN Elanco Animal Health Inc

Pharmaceutical Preparations · NYSE · SEC CIK 1739104 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.1%
TTM net income YoY-508.3%
TTM EPS YoY-528.6%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—

Margins

Gross margin56.2%
Operating margin—
Net margin-2.9%
FCF margin7.9%
EBITDA margin—

Returns

ROE-2.2%
ROA-1.1%
ROIC (approx.)—
Asset turnover0.38x

Leverage & solvency

Liabilities / assets50.3%
Debt / equity0.56x
Current ratio2.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-4.18x
Accruals ratio-5.7%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.71B$4.44B
Cost of revenue$2.12B$2.00B
Gross profit$2.59B$2.44B
R&D expense$368.00M$344.00M
SG&A expense$1.43B$1.31B
Pretax income-$224.00M$488.00M
Income tax$8.00M$150.00M
Net income-$232.00M$338.00M
EPS (basic)-0.470.68
EPS (diluted)-0.470.68
Weighted avg. shares (diluted)496.40M497.30M
Balance sheet
Cash & equivalents$545.00M$468.00M
Receivables$873.00M$805.00M
Inventory$1.74B$1.57B
Current assets$3.46B$3.21B
PP&E, net$1.41B$993.00M
Goodwill$4.78B$4.41B
Intangibles$3.41B$3.68B
Total assets$13.36B$12.61B
Current liabilities$1.60B$1.31B
Short-term debt$74.00M$44.00M
Long-term debt$3.94B$4.28B
Total debt$4.02B$4.32B
Total liabilities$6.81B$6.52B
Shareholders' equity$6.55B$6.10B
Net debt$3.47B$3.85B
Shares outstanding496.98M494.45M
Cash flow statement
Operating cash flow$560.00M$541.00M
Capital expenditure$276.00M$147.00M
Free cash flow$284.00M$394.00M
Investing cash flow-$279.00M$1.16B
Financing cash flow-$275.00M-$1.49B
Depreciation & amortization$680.00M$662.00M
Stock-based compensation$68.00M$55.00M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.